🔗 Share this article

While America undertakes unprecedented changes to its vaccination recommendations, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by questioning COVID-19 vaccinations throughout the global health crisis and has zeroed in on possible deaths after Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Schedule

Public health authorities had intended to announce major revisions to the childhood vaccination calendar earlier this month, bringing the US with the Danish vaccine program, sources say – a major change that would place the US at odds with much of the international standard with insufficient data for public health gain. This reveal has been delayed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to present at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this year.

A Shift at the Regulatory Body

This interim role might represent a closer partnership between the drug and biologics centers as Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has often pushed for halting some pediatric vaccine recommendations in the US to become more in line with the Danish model, a nation with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – usually the domain of Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Doubts Over Background

Høeg has no obvious track record in drug development, approval processes or leadership, which has been typical for former leaders of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for running the CDER, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Previous heads of the center would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she lacks the kind of background that former directors who ran the center have had.”

The drug center has an enormous range of responsibilities at the FDA, Woodcock stated.

“The public just pays attention on the innovative therapies, but the generic drug division approves a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and more, and all of those need to be managed,” Dr. Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative component to the position, which manages more than 5,000 staff members. “It’s a enormous administrative position, if you do it right,” the former official said.

Response and Disputed Policies

When asked about inquiries about Høeg’s fitness for the role and whether this appointment represents greater collaboration among FDA leaders on vaccines, a representative said that the “inquiries rely on flawed assumptions”.

“Her resume aligns with the responsibilities of her role,” the representative stated, citing the period Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's new priority voucher program, a contentious expedited therapy clearance system that apparently troubled her predecessors. “How are these drugs being picked for this fast-track system? Who is making the choices?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards more relaxed oversight of all drugs, aside from vaccines.”

Public Track Record on Immunizations

Regarding vaccines, Høeg has a more established, if concerning, track record, Howard said. She released a research paper using unconfirmed volunteer-provided data to determine the frequency of heart inflammation following COVID-19 immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Included in her “desired changes” for the current federal leadership encompassed altering guidelines for new vaccines and halting “unnecessary” vaccines, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has allegedly suggested barring young men from obtaining COVID-19 vaccines.

“She is an all-around true believer who starts off with her preconceived notions and reverse-engineers to retrofit the data in a extremely disingenuous, dishonest way,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg became part of other dissenters, {like|